Your briefing

Citi Raises Price Target on Alphabet Amid Strong YouTube, Search Data
Finance 6 days ago
Citi Raises Price Target on Alphabet Amid Strong YouTube, Search Data
Full Coverage

Smurfit WestRock Gains Investor Confidence with Price Target Boost
Finance 6 days ago
Smurfit WestRock Gains Investor Confidence with Price Target Boost
Full Coverage

Gap Inc. Outlook Brightens as Banana Republic and Athleta Show Recovery Potential
Finance 6 days ago
Gap Inc. Outlook Brightens as Banana Republic and Athleta Show Recovery Potential
Full Coverage

CAVA Group (NYSE:CAVA) Among Top Consumer Cyclical Picks Despite Lowered Q2 Outlook
Finance 6 days ago
CAVA Group (NYSE:CAVA) Among Top Consumer Cyclical Picks Despite Lowered Q2 Outlook
Full Coverage

Trending

1. Joann's closing
2. Texas Tech basketball
3. UNC basketball
4. Monster Hunter Wilds
5. Ketamine
6. Macron
7. UPMC Memorial shooting
8. Eagles
9. Hims stock
10. Joel Embiid

Popular News

BrightGene präsentiert positive Phase-2-Daten für den Dual-G...
1 week ago
BrightGene präsentiert positive Phase-2-Daten für den Dual-GLP-1R/GIPR-Agonisten zur Gewichtsregulation und Behandlung von Typ-2-Diabetes sowie präklinische Daten für ein neues Amylin-Analogon bei den 85 Wissenschaftlichen Sitzungen der American Diabetes Association

The mortgage market hopes for rate cuts amid war moves
1 week ago
The mortgage market hopes for rate cuts amid war moves

Ukraine returns bodies of 3 Russian soldiers repatriated as ...
1 week ago
Ukraine returns bodies of 3 Russian soldiers repatriated as remains of Ukrainians, Interior Ministry says

BrightGene presenteert positieve fase 2 gegevens voor de dua...
1 week ago
BrightGene presenteert positieve fase 2 gegevens voor de duale GLP-1R/GIPR agonist voor gewichtsbeheersing en type 2 diabetes, en preklinische gegevens voor een nieuw amylin-analoog tijdens de 85e wetenschappelijke sessies van de American Diabetes Association

BrightGene présente des données positives de phase 2 pour so...
1 week ago
BrightGene présente des données positives de phase 2 pour son agoniste double GLP-1R/GIPR dans la gestion du poids et le diabète de type 2, ainsi que des données précliniques pour un nouvel analogue de l'amylin, lors de la 85 e édition des Sessions Scientifiques de l'American Diabetes Association
About Us · Contact Us · Terms & Conditions · Help · Privacy ·

© Latest News Search Engine - Global and Local Breaking News 2025. All rights are reserved